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Background: Non-attendance at gynecological clinics is a major limitation of cervical cancer screening and
self-collection of samples may improve this situation. Although HPV testing of self-collected vaginal samples is
acceptable, the specificity is inadequate. The current focus is increasing self-collection of vaginal samples to
minimize clinic visits. In this study, we analyzed the concordance and clinical performance of DNA methylation
biomarker (PAX1, SOX1, and ZNF582) detection in self-collected vaginal samples and physician-collected cervical
samples for the identification of cervical neoplasm.
Methods: We enrolled 136 cases with paired methylation data identified from abnormal Pap smears (n = 126)
and normal controls (n = 10) regardless of HPV status at gynecological clinics. The study group comprised 37
cervical intraepithelial neoplasm I (CIN1), 23 cervical intraepithelial neoplasm II (CIN2), 16 cervical intraepithelial
neoplasm III (CIN3), 30 carcinoma in situ (CIS), 13 squamous cell carcinomas (SCCs) and seven adenocarcinomas
(ACs)/adenosquamous carcinomas (ASCs). PAX1, SOX1 and ZNF582 methylation in study samples was assessed by
real-time quantitative methylation-specific polymerase chain reaction analysis. We generated methylation index
cutoff values for the detection of CIN3+ in physician-collected cervical samples for analysis of the self-collected
group. Concordance between the physician-collected and self-collected groups was evaluated by Cohen’s
Kappa. Sensitivity, specificity and area under curve (AUC) were calculated for detection of CIN3+ lesions. Finally,
we produced an optimal cutoff value with the best sensitivity from the self-collected groups.
Results: We generated a methylation index cutoff value from physician-collected samples for detection of CIN3+.
There were no significant differences in sensitivity, specificity of PAX1, SOX1 and ZNF582 between the self-collected and
physician-collected groups. The methylation status of all three genes in the normal control samples, and the CIN 1,
CIN2, CIN3, CIS, ACs/ASCs and SCC samples showed reasonable to good concordance between the two groups
(κ = 0.443, 0.427, and 0.609 for PAX1, SOX1, and ZNF582, respectively). In determining the optimal cutoff values from
the self-collected group, ZNF582 showed the highest sensitivity (0.77; 95%CI, 0.65–0.87) using a cutoff value of 0.0204.
Conclusions: Methylation biomarker analysis of the three genes for detection of CIN3+ lesions shows reasonable to
good concordance between the self-collected and physician-collected samples. Therefore, self-collection of samples
could be adopted to decrease non-attendance and improve cervical screening.
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Cervical cancer remains one of the main causes of death
from cancer among women worldwide [1]. Cytology-
based screening has successfully reduced mortality asso-
ciated with cervical cancer [2]. However, the majority of
cases of cervical cancer are still associated with absent
or deficient screening. In previous studies, approximately
50 % of cervical cancers were diagnosed in women who
were not screened [3, 4]. Complete participation would
achieve a greater improvement in screening effectiveness
than intensifying screening policies [3]. Therefore, it is
important to improve participation rates among women
with a history of non-attendance.
Epidemiological studies have emphasized that human
papillomaviruses (HPVs) are the main etiological factor
for cervical cancer and that these viruses are present in
almost all cervical cancer tissues [5]. Screening partici-
pation rates for cervical cancer can be improved by
offering non-attending women the tools to collect a
vaginal sample at home. Self-collection is an acceptable
method to potentially increase participation [6]. Studies
have demonstrated that self-collected samples are suit-
able for HPV DNA testing and can increase participation
rates in primary screening for cervical cancer [6–11].
However, women whose self-collected specimens test
positive for high-risk HPV (hrHPV) require additional
triage testing because the specificity of assays for hrHPV
is insufficient to justify direct referral for colposcopy in
all cases [11, 12]. Although cytology is an accepted and
standard method of examination in triage for hrHPV-
positive women [13], cytological testing of self-collected
samples does not yield reliable results and a visit to a
physician is required [14].
In normal, precancerous and cervical cancer tissues,
the DNA methylation profiles of the host genome may
indicate tissue-specific perturbations that occur during
carcinogenesis [15]. DNA methylation leaves a heritable
record of such interactions and is an ideal biomarker for
cancer detection [16–20], which could be used to triage
possible cases of cervical cancer [21–24]. Previously, we
used a CpG island microarray approach to identify novel
genes that were silenced by methylation in cervical squa-
mous cell carcinoma (SCC) [25]. Quantitative analysis of
the PAX1 and SOX1 genes can be used effectively for
detection of cases of CIN that are grade 3 or worse
(CIN3+) [17]. Using methylated DNA sequence immu-
noprecipitation coupled with microarray analysis to
identify other genes with clinical applications, we found
that the gene for zinc finger protein 582 (ZNF582) was
highly methylated in SCC [18]. This gene is also highly
methylated in adenocarcinoma (AC) of the cervix [26].
In Taiwanese Gynecologic Oncology Group (TGOG) stud-
ies, we used a methylation biomarker and hrHPV tests to
detect CIN3+ lesions in low grade squamous intraepitheliallesions (LSIL). ZNF582 methylation is implicated as a
promising biomarker for use in the positive triage of cyto-
logical diagnoses of low grade squamous intraepithelial le-
sions [27]. Combined parallel testing using Pap smears and
PAX1 or SOX1 methylation tests may provide better per-
formance than a combination of Pap smears with HPV-
testing in detection of cervical neoplasm [28]. The clinical
performance of PAX1, SOX1, and ZNF582 as biomarkers
of cervical neoplasm has been validated in multi-center
clinical trials; therefore, analysis of changes in the methyla-
tion status of these genes could be applied for self-
collected vaginal samples.
The aim of this study was to validate the concordance
and clinical performance of PAX1, SOX1, and ZNF582
methylation for detection of CIN3+ lesions in self-
collected and physician-collected vaginal samples. Our
hope is that these genes will serve as sensitive methyla-




The flowchart illustrating the study design is shown in
Fig. 1. We randomly selected a sample set from women
attending our gynecologic outpatient department. All
women used a cytobrush (CooperSurgical, CT, USA) to
collect a vaginal sample as instructed by a physician.
Subsequently, a physician-collected cervical sample was
obtained.
Patients with normal cervixes (n = 10), and those with
CIN1 (n = 37), CIN2 (n = 23), CIN3 (n = 16), carcinoma
in situ (CIS) (n = 30), SCC (n = 13), and adenocarcinoma
(AC)/adenosquamous carcinoma (ASC) (n = 7) of the
uterine cervix participated in this study. Patients whose
cervical samples had normal cytology served as control
subjects. The patients were diagnosed, treated, and had
their tissues banked at the National Defense Medical
Center, Taipei, Taiwan as described [29]. All CINs and
invasive cancers were confirmed by histopathology.
Control patients were recruited from healthy women
who underwent routine Pap screening during the same
period. Exclusion criteria included pregnancy, chronic or
acute systemic viral infections, a history of cervical neo-
plasm, skin or genital warts, an immunocompromised
state, presence of other cancers, and previous surgery of
the uterine cervix.
Generation of methylation index cutoff values and clinical
accuracy calculation
Real-time quantitative methylation-specific polymerase
chain reaction (QMSP) was performed to assess the methy-
lation status of PAX1, SOX1 and ZNF582 in study samples.
We generated methylation index cutoff values from
physician-collected cervical samples for detection of
Fig. 1 The study design flowchart. All women used a cytobrush (CooperSurgical, CT, USA) to collect a vaginal sample as instructed by a physician.
Subsequently, a physician-collected cervical sample was obtained. Patients with abnormal Pap smear results were managed by colposcopy followed
by cervical biopsy or conization according to treatment guidelines. (CIN: cervical intraepithelial neoplasm, CIS: carcinoma in situ, SCC: squamous
cell carcinoma, AC: adenocarcinoma, ASC: adenosquamous carcinoma)
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area under curve (AUC) were calculated for detection of
CIN3+ lesions. Finally, we produced an optimal cutoff value
with the best sensitivity from the self-collected groups.
Real-time quantitative methylation-specific polymerase
chain reaction amplification of DNA
Genomic DNA was extracted from the collected specimens
using a protocol established for tissue banking. The con-
centration of DNA was determined using the Nanodrop
1000 (Thermo Fisher Scientific). QMSP was performed
after bisulfite treatment of denatured genomic DNA. Gene
symbols, primers, and probes for QMSP are available on re-
quest [17]. The COL2A gene was used as an internal refer-
ence to adjust the amount of input DNA by amplifying
non-CpG sequences in each sample. QMSP was performed
with a TaqMan probe system in a Roche LightCycler® 480
system. The 5′ and 3′ ends of the probes were labeled with
6-carboxy-fluorescein (6-FAM) and a quencher dye, re-
spectively. The 20 μL reaction mix contained 2 μL of bisul-
fite template DNA (2 μL), primers (250 nM each), TaqMan
probe (225 nM), and FastStart Universal Probe Master
(10 μL) (ROX, Roche). For the TaqMan-based QMSP,
each sample was analyzed in duplicate. The reactions
were performed by using an initial incubation at 95 °C
for 10 min, followed by 45 cycles of 95 °C for 15 s and
annealing and extension at the appropriate temperatures
for 1 min. The level of DNA methylation was described as
the methylation index (M-index) and calculated as follows:
10,000 × 2[(Cp of COL2A) – (Cp of gene)] [18]. The QMSP was
deemed to be a failure if the Cp value of COL2A was
higher than 36.
Ethics statement
Informed consent to participation in this study was ob-
tained from all patients and control subjects. This studywas conducted in accordance with the guidelines, and
with the approval of, the Ethics Committee of the Institu-
tional Review Boards of the Tri-Service General Hospital,
National Defense Medical Center (TSGHNDMCIRB-096-
05-090).Statistical analysis
Data were analyzed using the updated MedCalc ver-
sion 14. To determine the detection rate, CIN3 was
taken as a cutoff value for the QMSP analysis of three
genes in self-collected and physician-collected sam-
ples. The receiver operating characteristic (ROC) curve
was used to select the optimal cutoff value according
to the maxima of sensitivity and specificity to distin-
guish CIN3+ (including CIN3, CIS, SCC, AC and ASC)
and CIN2− (including normal controls, CIN1 and
CIN2) patients [30]. The McNemar test was used to
test the proportion of self-collected and physician-
collected samples in CIN3+ groups by the optimal
cutoff value of physician-collected. The concordance
between the self-collected and physician-collected samples
was measured by Cohen’s Kappa coefficient. Differences
with P-values less than 0.05 were considered to indicate
statistical significance.Results
Population, study design flowchart and cytology/histology
of study samples
We invited 136 women to participate in this study of
self-collected samples with paired methylation data from
samples of 10 normal control cervixes, 37 CIN1, 23
CIN2, 16 CIN3, 30 CIS, and 20 invasive cancers (13
SCCs and 7 ACs/ASCs) (Fig. 1). Details of the cytology/
histology and mean age of the subjects are shown in
Table 1.
Table 1 Cytology/histology and mean age of study participants
Diagnosis Cases Mean age ± SD
(n) (years)
Total 136 47.9 ± 12.9
Normal cytology 10 53.0 ± 16.2
CIN1 37 43.3 ± 11.3
CIN2 23 47.1 ± 14.3
CIN3 16 48.1 ± 12.5
CIS 30 48.0 ± 11.9
SCC 13 54.2 ± 11.6
AC/ASC 7 57.1 ± 14.9
SD Standard deviation, CIN1 cervical intraepithelial neoplasm type 1, CIN2 cervical
intraepithelial neoplasm type 2, CIN3 cervical intraepithelial neoplasm type 3, CIS
carcinoma in situ, SCC squamous cervical carcinoma, AC adenocarcinoma, ASC
adenosquamous carcinoma
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analysis of methylation biomarkers in self-collected and
physician-collected samples
We generated a methylation index cutoff value from
physician-collected samples for detection of CIN3+ and
then compared the methylation of PAX1, SOX1 and
ZNF582 genes in physician-collected and self-collected
samples. There were no significant differences in the
sensitivity and specificity of the QMSP analysis of PAX1,
SOX1, and ZNF582 between the self-collected and
physician-collected samples (Table 2). In addition, the
PAX1, SOX1, and ZNF582 methylation profiles in the
CIN3+ positive cases among the self-collected samples
were similar to those among the physician-collected
samples (percentage positive among self-collected sam-
ples: 60.6 %, 77.3 %, and 63.6 %, respectively; percentage
positive among physician-collected samples: 64.64 %,
74.24 %, and 60.61 %, respectively) (P = 0.81, 0.81, and
0.81, respectively; Table 2). Self-collection was found to
be comparable with physician-collected samples for the
detection of cervical methylation biomarkers (κ = 0.443,
0.427, and 0.609 for PAX1, SOX1, and ZNF582, respect-
ively; Fig. 2).
Optimization of the clinical accuracy of methylation
biomarkers using the cutoff values of the self-collected
group
The clinical performance of QMSP of ZNF582 in the self-
collected group was better than that in the physician-
collected group using a cutoff value generated from the
physician-collected group (sensitivity: 0.64; 95%CI, 0.51–
0.75 vs. 0.61 95%CI, 0.48–0.72, specificity: 0.87; 95%CI,
0.77–0.94 vs 0.83; 95%CI, 0.72–0.91; Table 2). Using a
ROC curve to obtain the best cutoff values from the self-
collected group, we found that QMSP of ZNF582 had the
highest sensitivity (0.77; 95%CI, 0.65–0.87) and specificity
(0.77; 95%CI, 0.66–0.86) (Table 3) at a cutoff value of0.0204. There were no differences in the AUCs of PAX1
and SOX1 between the self-collected and physician-
collected groups (0.731 vs. 0.727, P = 0.93 and 0.752 vs.
0.764, P = 0.80, respectively, Fig. 3). The AUC of ZNF582
in the self-collected group showed significantly better
clinical performance than that in the physician-collected
group (0.830 vs. 0.747, P = 0.04; Fig. 3).
Discussion
Our data showed reasonable to good concordance in the
DNA methylation the PAX1, SOX1, and ZNF582 genes
for detection of CIN3+ lesions between self-collected va-
ginal samples and physician-collected cervical samples.
These findings indicate that in the future, the require-
ment for patients to visit a physician for screening could
be reduced by submitting self-collected samples. Com-
pared with the current cytology-based call-recall pro-
grams, self-collected vaginal samples can increase access
to cervical screening and may help to further reduce the
incidence of cervical cancer by increasing the rate of
participation in screening programs [2, 11].
Our study for the comparison of the concordance of
methylation status between self-collected vaginal sam-
ples and physician-collected cervical samples was con-
ducted in a relatively large sample-size. Self-collection
was found to be comparable with physician-collected
samples for the detection of cervical methylation bio-
markers. This is consistent with other recent reports,
which have also shown high concordance in the results
of methylation analysis of self-sampled vaginal material
and physician-collected cervical scrapes [31]. Further-
more, our study was conducted using a relatively large
number of high-grade squamous intraepithelial neo-
plasm (HSIL, including CIN2, CIN3/CIS, SCC, AC/
ASC) samples, including seven cases of ACs/ASCs. In
addition, assessment of the methylation biomarkers in
ZNF582 provided the best clinical accuracy among self-
collected samples (AUC: 0.83; sensitivity, 0.77 (95%CI,
0.65–0.87); specificity, 0.77 (95%CI, 0.66–0.86), using a
cutoff of 0.0204). These results are comparable with
those of well-performed cytological testing, indicating
that methylation biomarker analysis of self-collected va-
ginal samples has the potential for use in population-
based studies comparing the clinical performance of
cytological testing for alternative methods of screening
of cervical cancer.
The limitation of this study is the restricted sample set,
especially in the normal controls, because we focused on
investigating the concordance between physician-collected
samples and self-collected samples obtained using a cyto-
brush. This device was designed for physician sampling
and is not particularly practical for use in self-collection
sampling. Consequently, the level of compliance and suc-
cess in obtaining a sample using this method was low













(Total, N = 70) (Total, N = 66) (Total N = 70) (Total N = 66)
PAX 1 0.014 16 42 0.64 0.77 17 40 0.61 0.76 0.81
(22.86 %) (64.64 %) (0.51 to 0.75) (0.66 to 0.86) (24.3 %) (60.6 %) (0.48 to 0.72) (0.64 to 0.85)
SOX1 0.156 18 49 0.74 0.74 25 51 0.77 0.64 0.81
(25.71 %) (74.24 %) (0.62 to 0.84) (0.62 to 0.84) (35.7 %) (77.3 %) (0.65 to 0.87) (0.52 to 0.75)
ZNF582 0.214 12 40 0.61 0.83 9 42 0.64 0.87 0.81
(17.14 %) (60.61 %) (0.48 to 0.72) (0.72 to 0.91) (12.9 %) (63.6 %) (0.51 to 0.75) (0.77 to 0.94)
Any of SOX1, PAX1 25 53 0.80 0.64 32 53 0.80 0.54 1.00
(35.71 %) (80.3 %) (0.69 to 0.89) (0.52 to 0.75) (44.7 %) (80.3 %) (0.69 to 0.89) (0.42 to 0.66)
Any of SOX1, ZNF582 22 53 0.80 0.69 27 53 0.80 0.61 1.00
(31.4 %) (80.3 %) (0.69 to 0.89) (0.56 to 0.79) (38.6 %) (80.3 %) (0.69 to 0.89) (0.49 to 0.73)
Any of PAX1, ZNF582 23 48 0.73 0.67 20 48 0.73 0.71 1.00
(32.9 %) (72.7 %) (0.60 to 0.83) (0.55 to 0.78) (28.6 %) (72.7 %) (0.60 to 0.83) (0.59 to 0.82)
Any one of three 29 57 0.86 0.59 34 55 0.83 0.51 0.75
(41.4 %) (86.4 %) (0.76 to 0.94) (0.46 to 0.70) (48.6 %) (83.3 %) (0.72 to 0.91) (0.39 to 0.64)
Any two of three 12 40 0.71 0.83 11 44 0.67 0.84 0.52
(17.1 %) (60.6 %) (0.48 to 0.72) (0.72 to 0.91) (15.7 %) (66.7 %) (0.5 to 0.78) (0.74 to 0.92)
CI confident interval
aThe optimal cutoff value of methylation index is identified in the physician-collected group and testing in the self-collected group












Fig. 2 Heat map of study patients in self-collected and physician-collected samples. Women with normal cervixes (n = 10), and those with CIN1
(n = 37), CIN2 (n = 23), CIN3 (n = 16), carcinoma in situ (CIS) (n = 30), SCC (n = 13), and adenocarcinoma (AC)/adenosquamous carcinoma (ASC)
(n = 7) of the uterine cervix participated in this study. The methylation status of all three genes are shown: dark, high methylation and light,
low methylation
Table 3 The optional cutoff value generated from self-collected samples for detection of CIN3+ in self-collected samples with
methylation of PAX1, SOX1 and ZNF582 genes
Cutoff
Pointa
Positive cases of CIN2- Positive cases of CIN3+ Sensitivity
(95 % CI)
Specificity
(95 % CI)(Total, N = 70) (Total, N = 66)
PAX1 0.0027 20 48 0.73 0.71
(28.6 %) (70.6 %) (0.60 to 0.83) (0.60 to 0.82)
SOX1 0.516 18 48 0.73 0.74
(25.7 %) (72.7 %) (0.60 to 0.83) (0.62 to 0.84)
ZNF582 0.0204 16 51 0.77 0.77
(22.9 %) (77.3 %) (0.65 to 0.87) (0.66 to 0.86
Any of SOX1, PAX1 28 57 0.86 0.60
(38.9 %) (86.3 %) (0.76 to 0.94) (0.48 to 0.72)
Any of SOX1, ZNF582 26 55 0.83 0.63
(36.1 %) (83.4 %) (0.72 to 0.91) (0.51 to 0.74)
Any of PAX1, ZNF582 28 59 0.89 0.60
(38.9 %) (89.4 %) (0.79 to 0.96) (0.48 to 0.72)
Any one of three 35 62 0.94 0.50
(50.0 %) (93.9 %) (0.85 to 0.98) (0.38 to 0.62)
Any two three 12 47 0.71 0.83
(17.1 %) (71.2 %) (0.59 to 0.82) (0.72 to 0.91)
CIN2 (including normal, CIN 1 and CIN 2), CIN3+ including CIN3, CIS, SCC, ASC and AC), CI confident interval
aThe optimal cutoff value of methylation index is identified in the self-collected group
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Fig. 3 Concordance in the clinical performance of methylation biomarkers between the self-collected and physician-collected groups. Receiver operat-
ing characteristic (ROC) curve analysis of PAX1, SOX1 and ZNF582. The area under curve (AUC) of the ROC curve of each gene was calculated for the
diagnosis of CIN3 and further progressed (CIN3+) lesions. Differences with P-values less than 0.05 were considered to indicate statistical significance
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were obtained. In addition, this was a hospital-based study
and so the results may not be representative of the general
population. A standardized education program and user-
friendly tools for self-collection are also warranted.
In developed countries with extensive infrastructure
for conducting cytological examinations, Pap smears
combined with methylation tests may perform better
than a combination of Pap smears with HPV-testing in
the detection of cervical neoplasm [28]. The reasons
underlying the lack of participation in screening pro-
grams among women in developed countries are com-
plex. Some examples of the barriers that have been
reported are practical, such as appointment times and
embarrassment [32]; therefore, creative and sensitive
methods that take into consideration these barriers to
participation in cervical cancer screening are required
[32]. Self-collected sampling is time-saving and avoids
embarrassment. For a non-attendee, self-collection of
samples for molecular screening of hrHPV could be a
suitable method for primary cervical cancer screening
followed by cytology-based triage. Although the detection
rate for CIN2+ or CIN3+ lesions is promising, cervical cy-
tology sampling still requires intervention by a clinician
[21, 23, 24]. Recent studies have used methylation bio-
markers to triage patients who screened positive for
hrHPV. The sensitivity of direct triage by combined ana-
lysis of the promoter methylation of miR-124-2 and the
MAL genes in self-collected cervicovaginal material was
similar to that of triage with cytological analysis of an
additional physician-collected smear [20]. The search for
complete methylation markers for use in triage of hrHPV-
positive women or in primary screening of cervical cancer
alone may further revolutionize cervical cancer screening.
Although self-collection of samples for hrHPV testing
is an acceptable method screening for hrHPV infection,insufficient specificity will lead false-positive results in
many patients in the absence of cervical neoplasm.
Triage of these patients is required to confirm a true
cervical intraepithelial neoplasm. Given the lack of infra-
structure for conducting cytological examinations in
low-resource areas, cytological screening is not ideal for
triage; furthermore, the sensitivity of this method varies
from 30 % to 87 % [33]. In contrast, only a few neoplas-
tic cells are required for the detection of promoter
methylation within a gene of interest using the QMSP
assay. We determined that the highest sensitivity values
for the detection of CIN3+ lesions by determining the
methylation status of PAX1, SOX1, and ZNF582 in self-
collected samples was 0.73, 0.73, and 0.77, respectively
(Table 3). The clinical performance of this type of assay
resembled that of a traditional cytological examination.
The potential use of these new biomarkers as tools for
cervical cancer screening as well as their possible use in
the developing world to triage hrHPV-positive women
during primary screening warrants further validation.
We used CIN3+ rather than CIN2+ as the cutoff in
our study because of the equivocal nature of CIN2 le-
sions when diagnosed and the heterogeneity of their
DNA methylation profiles [17, 34]. While only 5 % of
CIN2 lesions progress to invasive cancer and approxi-
mately 40 % regress, the corresponding percentages for
CIN3 lesions are 33 % and 12 %, respectively [35]. The
pathology of CIN2 lesions is not clearly defined and
these are the most difficult for pathologists to confirm
among all Pap smear diagnoses [36, 37]. The clinical
management of patients with CIN2 lesions should be
reassessed using the most accurate techniques. The in-
corporation of molecular markers, such as DNA methy-
lation profiles, into cervical cancer screening might help
to decrease the number of unnecessary referrals and re-
peat diagnostic procedures, which are not only a drain
Chang et al. BMC Cancer  (2015) 15:418 Page 8 of 9on financial resources but also inflict an unnecessary
burden on the patient. Additional studies are required to
define the nature of CIN2 lesions with or without DNA
methylation in longitudinal studies.
Conclusions
Our data confirm the reasonable to good concordance
between DNA methylation biomarker profiles analyzed
in self-collected and physician-collected samples for de-
tection of CIN3+ lesions. This indicates that cervical
cancer screening could be carried out not only on sam-
ples collected by physicians in a clinic setting, but also
on self-collected vaginal samples. To confirm our re-
sults, the performance of our assay should be evaluated
in prospective population-based clinical trials.
Abbreviations
PAX1: Paired box 1 gene; SOX1: Sex determining region Y-box 1; ZNF582: Zinc
finger protein 582; CIN1: Cervical intraepithelial neoplasm I; CIN2: Cervical
intraepithelial neoplasm II; CIN3: Cervical intraepithelial neoplasm III;
CIS: Carcinoma in situ; SCCs: Squamous cell carcinomas; ACs: Adenocarcinomas;
ASCs: Adenosquamous carcinomas; AUC: Area under curve; QMSP: Quantitative
methylation-specific polymerase chain reaction; HPV: Human papillomavirus;
hrHPV: High-risk HPV.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
Conception and design of the experiments: C-CC, H-CL. Performance of the
experiments: H-CW, P-HS and Y-WH. Analyses of the data: R-LH. Contribution
of reagents/materials/analysis tools: Y-PL, Y-WL. Drafting and editing of the
manuscript: C-CC, R-L and HH-CL. Recruitment of participants and collection
of clinical samples: C-CC, H-CL, C-YT, M-HY. All authors read and approved
the final manuscript.
Acknowledgements
This work was supported in part by the following grants: Grants number:
TSGH-C103-006-008-S01&S02&S03 from the Tri-Service General Hospital; NSC
102-2628-B-038-010-MY3 and NSC 103-2325-B-195-002 from Ministry of Science
and Technology; 103TMU-SHH-11 and TMUTOP103005-1 from Taipei Medical
University; the Teh-Tzer Study Group for Human Medical Research Foundation.
Author details
1Department of Obstetrics and Gynecology, Tri-Service General Hospital,
National Defense Medical Center, Taipei, Taiwan, Republic of China.
2Graduate Institute of Medical Sciences, National Defense Medical Center,
Taipei, Taiwan, Republic of China. 3Department of Obstetrics and
Gynecology, Shuang Ho Hospital, Taipei Medical University, Taipei, Taiwan,
Republic of China. 4Laboratory of Epigenetics and Cancer Stem Cells,
National Defense Medical Center, Taipei, Taiwan, Republic of China.
5Graduate Institute of Life Sciences, National Defense Medical Center, Taipei,
Taiwan, Republic of China. 6Department and Graduate Institute of
Microbiology and Immunology, National Defense Medical Center, Taipei,
Taiwan, Republic of China. 7Department of Obstetrics and Gynecology,
School of Medicine, College of Medicine, Taipei Medical University, Taipei,
Taiwan, Republic of China.
Received: 10 January 2015 Accepted: 30 April 2015
References
1. Forouzanfar MH, Foreman KJ, Delossantos AM, Lozano R, Lopez AD, Murray
CJ, et al. Breast and cervical cancer in 187 countries between 1980 and
2010: a systematic analysis. Lancet. 2011;378:1461–84.
2. Peto J, Gilham C, Fletcher O, Matthews FE. The cervical cancer epidemic
that screening has prevented in the UK. Lancet. 2004;364:249–56.3. Bos AB, Rebolj M, Habbema JD, van Ballegooijen M. Nonattendance is still
the main limitation for the effectiveness of screening for cervical cancer in
the Netherlands. Int J Cancer. 2006;119:2372–5.
4. de Bie RP, Vergers-Spooren HC, Massuger LF, Siebers AG, der Pol MR S-v,
Vedder JE, et al. Patients with cervical cancer: why did screening not prevent
these cases? Am J Obstet Gynecol. 2011;205(64):e61–7.
5. Zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical
application. Nat Rev Cancer. 2002;2:342–50.
6. Bosgraaf RP, Verhoef VM, Massuger LF, Siebers AG, Bulten J, de Kuyper-de
Ridder GM, et al. Comparative performance of novel self-sampling methods
in detecting high-risk human papillomavirus in 30,130 women not attending
cervical screening. Int J Cancer J Int du cancer. 2014;136:646–55.
7. Lazcano-Ponce E, Lorincz AT, Cruz-Valdez A, Salmeron J, Uribe P, Velasco-
Mondragon E, et al. Self-collection of vaginal specimens for human
papillomavirus testing in cervical cancer prevention (MARCH): a
community-based randomised controlled trial. Lancet. 2011;378:1868–73.
8. Virtanen A, Nieminen P, Luostarinen T, Anttila A. Self-sample HPV tests as an
intervention for nonattendees of cervical cancer screening in Finland: a
randomized trial. Cancer Epidemiol Biomarkers Prev. 2011;20:1960–9.
9. Zhao FH, Lewkowitz AK, Chen F, Lin MJ, Hu SY, Zhang X, et al. Pooled
analysis of a self-sampling HPV DNA test as a cervical cancer primary screening
method. J Natl Cancer Inst. 2012;104:178–88.
10. Szarewski A, Cadman L, Mesher D, Austin J, Ashdown-Barr L, Edwards R, et al.
HPV self-sampling as an alternative strategy in non-attenders for cervical
screening - a randomised controlled trial. Br J Cancer. 2011;104:915–20.
11. Snijders PJ, Verhoef VM, Arbyn M, Ogilvie G, Minozzi S, Banzi R, et al. High-risk
HPV testing on self-sampled versus clinician-collected specimens: a review on
the clinical accuracy and impact on population attendance in cervical cancer
screening. Int J Cancer. 2013;132:2223–36.
12. Cuzick J, Clavel C, Petry KU, Meijer CJ, Hoyer H, Ratnam S, et al. Overview of
the European and North American studies on HPV testing in primary
cervical cancer screening. Int J Cancer. 2006;119:1095–101.
13. Rijkaart DC, Berkhof J, Rozendaal L, van Kemenade FJ, Bulkmans NW,
Heideman DA, et al. Human papillomavirus testing for the detection of
high-grade cervical intraepithelial neoplasia and cancer: final results of the
POBASCAM randomised controlled trial. Lancet Oncol. 2012;13:78–88.
14. Garcia F, Barker B, Santos C, Brown EM, Nuno T, Giuliano A, et al. Cross-sectional
study of patient- and physician-collected cervical cytology and human
papillomavirus. Obstet Gynecol. 2003;102:266–72.
15. Farkas SA, Milutin-Gasperov N, Grce M, Nilsson TK. Genome-wide DNA
methylation assay reveals novel candidate biomarker genes in cervical
cancer. Epigenetics. 2013;8:1213–25.
16. Wentzensen N, Sherman ME, Schiffman M, Wang SS. Utility of methylation
markers in cervical cancer early detection: appraisal of the state-of-the-science.
Gynecol Oncol. 2009;112:293–9.
17. Lai HC, Lin YW, Huang RL, Chung MT, Wang HC, Liao YP, et al. Quantitative
DNA methylation analysis detects cervical intraepithelial neoplasms type 3
and worse. Cancer. 2010;116:4266–74.
18. Huang RL, Chang CC, Su PH, Chen YC, Liao YP, Wang HC, et al. Methylomic
analysis identifies frequent DNA methylation of zinc finger protein 582
(ZNF582) in cervical neoplasms. PLoS One. 2012;7:e41060.
19. Sova P, Feng Q, Geiss G, Wood T, Strauss R, Rudolf V, et al. Discovery of
novel methylation biomarkers in cervical carcinoma by global
demethylation and microarray analysis. Cancer Epidemiol Biomarkers Prev.
2006;15:114–23.
20. Verhoef VM, Bosgraaf RP, van Kemenade FJ, Rozendaal L, Heideman DA,
Hesselink AT, et al. Triage by methylation-marker testing versus cytology in
women who test HPV-positive on self-collected cervicovaginal specimens
(PROHTECT-3): a randomised controlled non-inferiority trial. Lancet Oncol.
2014;15:315–22.
21. Hesselink AT, Heideman DA, Steenbergen RD, Coupe VM, Overmeer RM,
Rijkaart D, et al. Combined promoter methylation analysis of CADM1 and MAL:
an objective triage tool for high-risk human papillomavirus DNA-positive
women. Clin Cancer Res. 2011;17:2459–65.
22. Overmeer RM, Louwers JA, Meijer CJ, van Kemenade FJ, Hesselink AT,
Daalmeijer NF, et al. Combined CADM1 and MAL promoter methylation
analysis to detect (pre-)malignant cervical lesions in high-risk HPV-positive
women. Int J Cancer. 2011;129:2218–25.
23. Hansel A, Steinbach D, Greinke C, Schmitz M, Eiselt J, Scheungraber C, et al.
A promising DNA methylation signature for the triage of high-risk human
papillomavirus DNA-positive women. PLoS One. 2014;9:e91905.
Chang et al. BMC Cancer  (2015) 15:418 Page 9 of 924. Eijsink JJ, Lendvai A, Deregowski V, Klip HG, Verpooten G, Dehaspe L, et al.
A four-gene methylation marker panel as triage test in high-risk human
papillomavirus positive patients. Int J Cancer. 2012;130:1861–9.
25. Lai HC, Lin YW, Huang TH, Yan P, Huang RL, Wang HC, et al. Identification
of novel DNA methylation markers in cervical cancer. Int J Cancer.
2008;123:161–7.
26. Chang CC, Huang RL, Wang HC, Liao YP, Yu MH, Lai HC. High methylation
rate of LMX1A, NKX6-1, PAX1, PTPRR, SOX1, and ZNF582 genes in cervical
adenocarcinoma. Int J Gynecol Cancer. 2014;24:201–9.
27. Lin H, Chen TC, Chang TC, Cheng YM, Chen CH, Chu TY, et al. Methylated
ZNF582 gene as a marker for triage of women with Pap smear reporting
low-grade squamous intraepithelial lesions - a Taiwanese Gynecologic
Oncology Group (TGOG) study. Gynecol Oncol. 2014;135:64–8.
28. Lai HC, Ou YC, Chen TC, Huang HJ, Cheng YM, Chen CH, et al. PAX1/SOX1
DNA methylation and cervical neoplasia detection: a Taiwanese Gynecologic
Oncology Group (TGOG) study. Cancer medicine. 2014;3:1062–74.
29. Chu TY, Hwang KS, Yu MH, Lee HS, Lai HC, Liu JY. A research-based tumor
tissue bank of gynecologic oncology: characteristics of nucleic acids extracted
from normal and tumor tissues from different sites. Int J Gynecol Cancer.
2002;12:171–6.
30. Youden WJ. Index for rating diagnostic tests. Cancer. 1950;3:32–5.
31. Boers A, Bosgraaf RP, van Leeuwen RW, Schuuring E, Heideman DA,
Massuger LF, et al. DNA methylation analysis in self-sampled brush material
as a triage test in hrHPV-positive women. Br J Cancer. 2014;111:1095–101.
32. Waller J, Jackowska M, Marlow L, Wardle J. Exploring age differences in
reasons for nonattendance for cervical screening: a qualitative study. BJOG.
2012;119:26–32.
33. Nanda K, McCrory DC, Myers ER, Bastian LA, Hasselblad V, Hickey JD, et al.
Accuracy of the Papanicolaou test in screening for and follow-up of cervical
cytologic abnormalities: a systematic review. Ann Intern Med. 2000;132:810–9.
34. Holowaty P, Miller AB, Rohan T, To T. Natural history of dysplasia of the
uterine cervix. J Natl Cancer Inst. 1999;91:252–8.
35. Ostor AG. Natural history of cervical intraepithelial neoplasia: a critical
review. Int J Gynecol Pathol. 1993;12:186–92.
36. Stoler MH, Schiffman M. Atypical Squamous Cells of Undetermined
Significance-Low-grade Squamous Intraepithelial Lesion Triage Study G:
Interobserver reproducibility of cervical cytologic and histologic interpretations:
realistic estimates from the ASCUS-LSIL Triage Study. Jama. 2001;285:1500–5.
37. Carreon JD, Sherman ME, Guillen D, Solomon D, Herrero R, Jeronimo J, et al.
CIN2 is a much less reproducible and less valid diagnosis than CIN3: results
from a histological review of population-based cervical samples. Int J Gynecol
Pathol. 2007;26:441–6.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
